ETOMIDATE INJECTION USP SOLUTION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

ETOMIDATE

Fáanlegur frá:

MARCAN PHARMACEUTICALS INC

ATC númer:

N01AX07

INN (Alþjóðlegt nafn):

ETOMIDATE

Skammtar:

2MG

Lyfjaform:

SOLUTION

Samsetning:

ETOMIDATE 2MG

Stjórnsýsluleið:

INTRAVENOUS

Einingar í pakka:

15G/50G

Gerð lyfseðils:

Prescription

Vörulýsing:

Active ingredient group (AIG) number: 0162234001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2022-03-02

Vara einkenni

_Etomidate Injection USP _
_Page 1 of 28_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ETOMIDATE INJECTION USP
Solution, 2 mg/mL, Intravenous
USP
General Anesthetic
Marcan Pharmaceuticals Inc.
Date of Initial Authorization:
2 Gurdwara Road, Suite #112
FEB 18, 2022
Ottawa, ON K2E 1A2
Submission Control Number: 254122
_Etomidate Injection USP _
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
......................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
1.
INDICATIONS
...................................................................................................................................
3
1.1
Pediatrics
....................................................................................................................................
3
1.2
Geriatrics
....................................................................................................................................
3
2
CONTRAINDICATIONS
....................................................................................................................
3
3
DOSAGE AND ADMINISTRATION
...................................................................................................
4
3.1
Dosing Considerations
................................................................................................................
4
3.2
Recommended Dose and Dosage Adjustment
............................................................................
4
3.3
Administration
.......................................................................................................................